Adalimumab
The risk or severity of infection and neutropenia can be increased when Adalimumab is combined with Canakinumab.
Anakinra
The risk or severity of infection can be increased when Anakinra is combined with Canakinumab.
Anhydrous Tacrolimus
Tacrolimus may increase the immunosuppressive activities of Canakinumab.
Advertisement
Anthrax immune globulin, human
The risk or severity of adverse effects can be increased when Canakinumab is combined with Anthrax immune globulin human.
BCG Vaccine
The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Canakinumab.
BCG, Live, Connaught Strain
The risk or severity of adverse effects can be increased when Canakinumab is combined with Bacillus calmette-guerin substrain connaught live antigen.
Advertisement
BCG, Live, Tice Strain
The risk or severity of adverse effects can be increased when Canakinumab is combined with Bacillus calmette-guerin substrain tice live antigen.
Certolizumab Pegol
The risk or severity of infection and neutropenia can be increased when Certolizumab pegol is combined with Canakinumab.
Denosumab
The risk or severity of adverse effects can be increased when Denosumab is combined with Canakinumab.
Advertisement
Etanercept
The risk or severity of infection and neutropenia can be increased when Etanercept is combined with Canakinumab.
Fingolimod
Canakinumab may increase the immunosuppressive activities of Fingolimod.
Golimumab
The risk or severity of infection and neutropenia can be increased when Golimumab is combined with Canakinumab.
Hepatitis A Vaccine, Inactivated
The risk or severity of adverse effects can be increased when Canakinumab is combined with Hepatitis A Vaccine.
Hepatitis B Surface Antigen Vaccine
The risk or severity of adverse effects can be increased when Canakinumab is combined with Hepatitis B Vaccine (Recombinant).
Infliximab
The risk or severity of infection and neutropenia can be increased when Infliximab is combined with Canakinumab.
Infliximab-Abda
The risk or severity of infection and neutropenia can be increased when Infliximab is combined with Canakinumab.
Infliximab-Dyyb
The risk or severity of infection and neutropenia can be increased when Infliximab is combined with Canakinumab.
Leflunomide
The risk or severity of adverse effects can be increased when Canakinumab is combined with Leflunomide.
Natalizumab
The risk or severity of adverse effects can be increased when Canakinumab is combined with Natalizumab.
Ocrelizumab
Ocrelizumab may increase the immunosuppressive activities of Canakinumab.
Pimecrolimus
The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Canakinumab.
Pirfenidone
The risk or severity of infection and neutropenia can be increased when Pirfenidone is combined with Canakinumab.
Rabies Immune Globulin, Human
The risk or severity of adverse effects can be increased when Canakinumab is combined with Human rabies virus immune globulin.
Rabies Virus Vaccine Flury-Lep Strain
The risk or severity of adverse effects can be increased when Canakinumab is combined with Rabies virus inactivated antigen, A.
Roflumilast
Roflumilast may increase the immunosuppressive activities of Canakinumab.
ROTAVIRUS VACCINE, LIVE
The risk or severity of adverse effects can be increased when Canakinumab is combined with Rotavirus Vaccine.
Rubella Virus Vaccine Live (wistar Ra 27-3 Strain)
The risk or severity of adverse effects can be increased when Canakinumab is combined with Rubella virus vaccine.
Salmonella enterica subsp. enterica serovar typhi
The risk or severity of adverse effects can be increased when Canakinumab is combined with Salmonella typhi ty21a live antigen.
sipuleucel-T
The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Canakinumab.
Tacrolimus
Tacrolimus may increase the immunosuppressive activities of Canakinumab.
Tetanus Toxoid Vaccine, Inactivated
The risk or severity of adverse effects can be increased when Canakinumab is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).
Tofacitinib
Canakinumab may increase the immunosuppressive activities of Tofacitinib.
Trastuzumab
Trastuzumab may increase the neutropenic activities of Canakinumab.
Typhoid Vaccine Live Ty21a
The risk or severity of adverse effects can be increased when Canakinumab is combined with Salmonella typhi ty21a live antigen.
Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain
The risk or severity of adverse effects can be increased when Canakinumab is combined with Salmonella typhi ty2 vi polysaccharide antigen.
Varicella Virus Vaccine Live (Oka-Merck) strain
The risk or severity of adverse effects can be increased when Canakinumab is combined with Varicella Zoster Vaccine (Live/Attenuated).
Yellow Fever Vaccine
The risk or severity of adverse effects can be increased when Canakinumab is combined with Yellow Fever Vaccine.
Yellow-Fever Virus Vaccine, 17D-204 strain
The risk or severity of adverse effects can be increased when Canakinumab is combined with Yellow Fever Vaccine.
